In accordance with a possible influence of MS-risk alleles on the activity of STAT-pathways, we investigated signaling properties of the IL-6- and IL-23-induced STAT3-pathway and of the IL-12-induced STAT4-pathway in T, B, and NK cells from patients with RRMS and healthy controls. This evidence concerns the gene IL6 and myeloid sarcoma.